Analysis of GD2/GM2 synthase mRNA as a biomarker for small cell lung cancer
Authors:
- Andrew B. BrownABAndrew B. Brown
- Irene Y. CheungICIrene Y. Cheung
- Nai-Kong V. CheungNCNai-Kong V. Cheung
- Mark G. KrisMKMark G. Kris
- Lee M. KrugLKLee M. Krug
- 1 February 2010
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 67 (2) , 216-220
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 2007
- Measuring circulating neuroblastoma cells by quantitative reverse transcriptase–polymerase chain reaction analysisCancer, 2004
- Early Molecular Response of Marrow Disease to Biologic Therapy Is Highly Prognostic in NeuroblastomaJournal of Clinical Oncology, 2003
- GD2 synthaseCancer, 2001
- Detection of neuroblastoma in bone marrow by immunocytology: Is a single marrow aspirate adequate?Medical and Pediatric Oncology, 1999
- Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosidesInternational Journal of Cancer, 1997
- Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system.Proceedings of the National Academy of Sciences, 1996
- Targeting of small-cell lung cancer using the anti-GD2 ganglioside monoclonal antibody 3F8: A pilot trialEuropean Journal of Nuclear Medicine and Molecular Imaging, 1996
- Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient Southwest Oncology Group data base.Journal of Clinical Oncology, 1990
- Developmental Changes in Ganglioside Composition and Synthesis in Embryonic Rat BrainJournal of Neurochemistry, 1988